Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Marinus Pharma CS
(NQ:
MRNS
)
1.330
+0.070 (+5.56%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Marinus Pharma CS
< Previous
1
2
3
4
5
6
7
Next >
Marinus Pharmaceuticals Announces Virtual R&D Event on October 5, 2021
September 28, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Ganaxolone in CDKL5 Deficiency Disorder
September 20, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 09, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
European Medicines Agency Grants Marinus Pharmaceuticals Accelerated Assessment of Ganaxolone for Treatment of CDKL5 Deficiency Disorder
August 26, 2021
From
Marinus Pharmaceuticals, Inc.
Via
Business Wire
Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences
August 25, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Reports Topline Ganaxolone Phase 2 Open-Label Results in Tuberous Sclerosis Complex and Receives FDA Orphan Drug Designation
August 17, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results
August 10, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 06, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Provide Business Update and Announce Second Quarter 2021 Financial Results on August 10, 2021
August 03, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of Ganaxolone
August 03, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Submits New Drug Application (NDA) to FDA for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder and Provides Pipeline Update
August 03, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Santiago Arroyo, M.D., Ph.D.
July 01, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 22, 2021
From
Marinus Pharmaceuticals, Inc.
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 14, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences
June 11, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results
May 17, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Reschedules First Quarter 2021 Financial Results Conference Call
May 13, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Provide Business Update and Announce First Quarter 2021 Financial Results on May 13, 2021
May 07, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences
April 28, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 12, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Bolsters Leadership Team with Two New Appointments
April 12, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.